Parkinson's disease, the second most common type of progressive dementia after Alzheimer's disease, affects nearly 1 million people in the U.S. and an estimated 10 million individuals worldwide. Each ...

A recent study published in The New England Journal of Medicine has demonstrated that lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may slow the progression of motor disability in ...

For years, researchers have watched the tiny power plants inside brain cells falter in Parkinson’s disease and wondered what ...

Vertero Therapeutics, a clinical-stage biotechnology company breaking barriers in neurodegenerative disease treatment, today announced that it has initiated a Phase 1 study of its lead candidate, ...

Parkinson's disease (PD) has been a widely known debilitative neurodegenerative condition affecting millions of people worldwide. While it's often mistakenly assumed to be a fatal illness, Parkinson's ...

Your T cells work hard to fight disease. Unfortunately, "friendly fire" from T cells can sometimes harm the body's healthy tissues. For people with autoimmune disease, T cell reactivity is a big ...

Parkinson's disease, a degenerative brain condition primarily marked by the loss of muscle control, has been thrust into the media over the years in film and television. But there's still a ton of ...

A highly popular class of drugs for diabetes and obesity is showing early potential to help patients with Parkinson's disease, too. In a mid-stage trial, an older diabetes treatment called ...